Search Results for: Advanced Cell Technology

Advanced Cell Technology pub: Trial for Macular Degeneration

ACT-FIgure-1-

The stem cell biotech Advanced Cell Technology (ACT) reported new, positive data in a paper in Lancet from their clinical trials using retinal pigmented epithelial cells (RPEs) made from human embryonic stem cells (hESC) for treatment of different forms of macular degeneration (MD). The paper was entitled “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related …

Advanced Cell Technology pub: Trial for Macular Degeneration Read More »

Advanced Cell Technology (ACT) Revs Up Pre-Clinical Studies for MS

advanced-cell-technology

There is more good news from leading stem cell biotech Advanced Cell Technology (ACT) on preclinical rodent studies using stem cells to treat mice with an MS-like condition. They published a new paper in the journal Stem Cell Reports entitled “Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of …

Advanced Cell Technology (ACT) Revs Up Pre-Clinical Studies for MS Read More »

Big Changes Unfolding at Advanced Cell Technology (ACTC)

advanced-cell-technology

Stem cell biotech, Advanced Cell Technology (ACT; stock symbol ACTC), has started off 2014 with indications that it is in a phase of rapid evolution. Some changes, such as today’s announced departure of now former CEO Gary Rabin (see my 2013 interview with him here), are already in the public domain, but other big developments …

Big Changes Unfolding at Advanced Cell Technology (ACTC) Read More »

Interview with Gary Rabin of Advanced Cell Technology (ACT)

Gary-Rabin-headshot-formatted-5.25

One of the more exciting stem cell biotechs out there today is Advanced Cell Technology (ACT). At this time ACT has the only two ES cell-based FDA-approved clinical trials ongoing and so far they have looked quite promising in terms of preliminary safety data. However, ACT has much more in the pipeline including potentially iPS …

Interview with Gary Rabin of Advanced Cell Technology (ACT) Read More »

Stem cell biotech of the year 2012: Advanced Cell Technology (ACTC)

For the second year in a row (see awards 2011), Advanced Cell Technology (ACT; stock symbol ACTC) is my stem cell biotech of the year. Their trials for different forms of macular degeneration (here and here and here) are progressing well and as a stem cell scientist I really appreciate the fact they are publishing their …

Stem cell biotech of the year 2012: Advanced Cell Technology (ACTC) Read More »

Advanced Cell Technology (ACTC) announces plan to make iPS cell-derived platelets: some thoughts

Advanced Cell Technology (ACT) is well into clinical trials for macular degeneration (the leading cause of blindness) using human embryonic stem cell (hESC)-based retinal pigmented epithelial cells (RPE). To date, the trials suggest the products are safe. Efficacy? We don’t know. I am cautiously hopeful, but it is frustrating to know that most clinical trials …

Advanced Cell Technology (ACTC) announces plan to make iPS cell-derived platelets: some thoughts Read More »

Stem Cell Biotech Advanced Cell Technology (ACT) gets $35 million

Advanced Cell Technology (ACT; stock symbol ACTC) announced that it has secured $35 million in funding from investment company, Lincoln Park Capital. The press release quotes CEO Gary Rabin: “We are most pleased about this financing agreement, as it has a number of notable benefits for the company,” commented Gary Rabin, chairman and CEO of …

Stem Cell Biotech Advanced Cell Technology (ACT) gets $35 million Read More »

Why I finally bought stock in Advanced Cell Technology

advanced-cell-technology

Today after years of following the company Advanced Cell Technology (ACT), I finally bought stock (ACTC) in it. Why? As a stem cell researcher myself working on human ES cells, iPS cells, and many other types of stem cells, I have been following ACT for years, but have never pulled the trigger to buy their stock….until …

Why I finally bought stock in Advanced Cell Technology Read More »

Advanced Cell Technology and Geron: allies or competitors?

Geron-300x2212

Two companies, Advanced Cell Technology (ACT) and Geron, both HQ’d here in California, have FDA-approved early stage clinical trials in the works. Geron’s trial has already started and reportedly now has enrolled at least two patients. The trial is of course for the safety of Geron’s GRNOPC1 oligodendrocyte product made from human ES cells for …

Advanced Cell Technology and Geron: allies or competitors? Read More »

3 cell therapy companies doing well: Vertex, Vericel, & Regeneron

Vericel, Cell Therapy Companies

Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy …

3 cell therapy companies doing well: Vertex, Vericel, & Regeneron Read More »